Regular aspirin use and lung cancer risk Kirsten B. Moysich, Adrienne Ronsani, Ravi J. Menezes, Helen Swede, K. Michael Cummings, Andrew Hyland, Gerold Bepler Roswell Park Cancer Institute, Buffalo, NY; University of Massachusetts, Amherst, MA. Although a large number of epidemiological studies have examined the role of aspirin in the chemoprevention of colon cancer and other solid tumors, there is little research focusing on the association between aspirin and lung cancer risk. We conducted a hospital case-control study to evaluate the role of regular aspirin use in lung cancer etiology. Study participants included 868 cases with primary, incident lung cancer and 935 hospital controls with non-neoplastic conditions who completed a comprehensive epidemiological questionnaire. Participants were classified as regular aspirin users if they had taken the drug at least once a week for at least one year. Unconditional logistic regression analysis was used to compute crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs). Results indicated that lung cancer risk was significantly lower for aspirin users compared to non-users (adjusted OR=0.57; 95% CI 0.41-0.78). Although there was no clear evidence of a dose-response relationship, we observed risk reductions associated with greater frequency of use. Compared to participants classified as non-users, those who reported to have used aspirin one to six times per week (adjusted OR=0.53; 95% CI 0.28-0.99) and more than seven times per week (adjusted OR=0.58; 95% CI 0.41-0.82) were at significantly lower lung cancer risk. Similarly, prolonged duration of use was associated with reduced lung cancer risk, with adjusted ORs of 0.56 (95% CI 0.39-0.79) for one to ten years of use and 0.61 (95% CI 0.34-1.09) for 11 or more years of use, respectively. We observed a linear inverse association with decreasing risk as a function of increasing tablet years (tablets per day x years of use). In comparison to non-users, those participants with one to ten calculated tablet years had a 37% (95% CI 0.44-0.92) risk reduction, whereas those with more than 11 tablet years had a more than 50% (95% CI 0.27-0.77) decrease in risk. These results were virtually unchanged when the sample was restricted to current and former smokers, although several risk estimates were not statistically significant, due to the decline in sample size. Results from this hospital-based case-control study suggest that regular aspirin use may be associated with reduced risk of lung cancer. Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.